Cargando…

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach

PURPOSE: The existing panels of COVID-19 vaccines are based on the spike protein of an earlier SARS-CoV-2 strain that emerged in Wuhan, China. However, the evolving nature of SARS-CoV-2 has resulted in the emergence of new variants, thereby posing a greater challenge in the management of the disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranjan, Prashant, Neha, Devi, Chandra, Jain, Garima, Mallick, Chandana Basu, Das, Parimal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Indian Association of Medical Microbiologists. Published by Elsevier B.V. 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971047/ https://www.ncbi.nlm.nih.gov/pubmed/35370005 http://dx.doi.org/10.1016/j.ijmmb.2022.03.009

Ejemplares similares

Characterization of mutations modulating enhanced transmissibility of SARS-CoV-2 B.1.617+ (Delta) variant using In Silico tools
por: Shahhosseini, Nariman
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
por: Hu, Jie, et al.
Publicado: (2021)

The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach
por: Ranjan, Prashant, et al.
Publicado: (2022)

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2021)

Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach
por: Seadawy, Mohamed G., et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Variant-specific RT-qPCR for rapid screening of B.1.617 mutations in SARS-CoV-2
por: Jallul, Mwada, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021)

Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617
por: Fan, Lin-qian, et al.
Publicado: (2021)

SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
por: Pascarella, Stefano, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2022)

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
por: Augusto, Gilles, et al.
Publicado: (2021)

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
por: Ferreira, Isabella A T M, et al.
Publicado: (2021)

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
por: Wilhelm, Alexander, et al.
Publicado: (2021)

Urinary extracellular vesicles miRNA—A new era of prostate cancer biomarkers
por: Jain, Garima, et al.
Publicado: (2023)

Rapid Automated Screening for SARS-CoV-2 B.1.617 Lineage Variants (Delta/Kappa) through a Versatile Toolset of qPCR-Based SNP Detection
por: Nörz, Dominik, et al.
Publicado: (2021)

Emerging Variants of B.1.617 Lineage Identified Among Returning Chinese Employees Working in India — Chongqing Municipality, China, April 2021
por: Ye, Sheng, et al.
Publicado: (2021)

Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant
por: Antony, Priya, et al.
Publicado: (2021)

The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
por: Li, Gen, et al.
Publicado: (2021)

The surgions mate, 1617
Publicado: (1979)

Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure
por: Hajj-Hassan, Houssein, et al.
Publicado: (2021)

Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
por: Khan, Mohd Imran, et al.
Publicado: (2021)

In silico investigations of heparin binding to SARS‐CoV‐2 variants with a focus at the RBD/ACE2 interface
por: Ali, Nemat, et al.
Publicado: (2022)

Detection of Variants of B.1.617 Lineage from Five Returning Chinese Nationals at a Guangxi-Vietnam Border Port — Guangxi Zhuang Autonomous Region, China, April 2021
por: Kang, Ning, et al.
Publicado: (2021)

Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility
por: Hanai, Toshihiko
Publicado: (2022)

In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine
por: Masoomi Nomandan, Seyedeh Zeinab, et al.
Publicado: (2022)

1617. Assessment of Bloodstream Infections in Patients with Intrapartum Fever
por: Kamel, Barbara, et al.
Publicado: (2023)

Enhanced fitness of SARS-CoV-2 B.1.617.2 Delta variant in ferrets
por: Sun, Xiangjie, et al.
Publicado: (2023)

The Dominance of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 and Its Sublineages and Associations with Mortality during the COVID-19 Pandemic in India between 2020 and 2021
por: Venkatraja, Bakilapadavu, et al.
Publicado: (2022)

A SARS-CoV-2 vaccine candidate: In-silico cloning and validation
por: Bhattacharya, Manojit, et al.
Publicado: (2020)

Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies
por: Singh, Jaikee Kumar, et al.
Publicado: (2023)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach
por: Avelar, Mayra, et al.
Publicado: (2023)

The Worshipful Society of Apothecaries of London: A History, 1617–1967
por: Trail, R. R.
Publicado: (1969)

A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
por: Mlcochova, Petra, et al.
Publicado: (2021)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
por: Valério, Mariana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9eupocpk4e1nbam2b927tjf1rf